2m 2m 2m 2m 2m 2m 2m
JASPER THERAPEU (JSPR)
NASDAQ
$0.51-$0.04 (-7.13%)
Price as of Jun 03, 2026 7:20 PM EDT- $23.2MMarket Cap
- -90.66%1-Year Change
- BiotechnologyIndustry
JASPER THERAPEU (JSPR)
$0.51-$0.04 (-7.13%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | -246,000 N/A | N/A N/A | |
Cost of Revenue | 6.7M +380.50% | 1.4M N/A | N/A N/A | 1.2M 0.00% | |
Gross Profit | -6.7M +380.50% | -1.4M +469.11% | -246,000 -79.50% | -1.2M -6.25% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -63.1M +13.05% | -55.8M +7.79% | -51.8M +49.55% | -34.6M +36.21% | |
Depreciation and Amortization Expense | 1.1M -23.09% | 1.4M +23.92% | 1.1M +13.64% | 975,000 +158.62% | |
Total Operating Expenses | 83.9M +10.03% | 76.2M +10.71% | 68.9M +34.50% | 51.2M +38.99% | |
Operating Profit | -83.9M +10.03% | -76.2M +10.71% | -68.9M +34.50% | -51.2M +38.99% | |
Interest Income | 1.7M -65.58% | 5.1M -2.71% | 5.2M N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -246,000 N/A | N/A N/A | |
Interest Income and Expense and Net | 1.7M -65.58% | 5.1M +2.12% | 5.0M N/A | 0 +100.00% | |
Total Nonoperating Income and Expense | 8.1M +62.62% | 5.0M +2,120.33% | -246,000 -141.98% | 586,000 +832.50% | |
Income before Taxes | -83.9M +10.03% | -76.2M +10.71% | -68.9M +34.50% | -51.2M +67.11% | |
Income Taxes | N/A N/A | 2,000 N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -75.8M +6.36% | -71.3M +10.55% | -64.5M +71.06% | -37.7M +23.00% | |
Net Income from Continuing Operations Applicable to Common | -75.8M +6.36% | -71.3M +10.55% | -64.5M +71.06% | -37.7M +23.00% | |
Basic EPS and Net Income | -3.95 -19.22% | -4.89 -20.87% | -6.18 +500.00% | -1.03 -61.71% | |
Diluted EPS and Net Income | -3.95 -19.22% | -4.89 -20.87% | -6.18 +500.00% | -1.03 -61.71% | |
Basic Weighted Average Shares | 19.2M +31.42% | 14.6M +39.71% | 10.4M -71.39% | 36.5M +220.20% | |
Diluted Weighted Average Shares | 19.2M +31.42% | 14.6M +39.71% | 10.4M -71.39% | 36.5M +220.20% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 28.7M -59.95% | 71.6M -17.55% | 86.9M +127.16% | 38.3M -54.84% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 28.7M -59.95% | 71.6M -17.55% | 86.9M +127.16% | 38.3M -54.84% | |
Total Current Assets | 34.6M -54.30% | 75.8M -14.76% | 88.9M +113.12% | 41.7M -52.49% | |
Accumulated Depreciation | 4.8M +26.45% | 3.8M +54.76% | 2.5M +81.95% | 1.4M +258.62% | |
Property and Plant and Equipment and Net | 102,000 -94.56% | 1.9M -31.24% | 2.7M -23.57% | 3.6M -3.20% | |
Total Long-Term Assets | 113,000 -86.22% | 820,000 -38.94% | 1.3M +76.94% | 759,000 +17.67% | |
Total Assets | 35.8M -55.22% | 79.9M -15.80% | 94.9M +96.22% | 48.4M -48.36% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 400,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 13.2M -13.37% | 15.2M +23.14% | 12.4M +75.15% | 7.1M -11.91% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 2.3M 0.00% | 2.3M 0.00% | 2.3M -3.78% | 2.4M -1.13% | |
Total Liabilities | 31.6M +73.54% | 18.2M +10.78% | 16.5M +32.98% | 12.4M -48.74% | |
Retained Earnings | -316.7M +31.47% | -240.9M +42.02% | -169.6M +61.32% | -105.1M +55.87% | |
Total Stockholders Equity | 4.2M -93.27% | 61.7M -21.37% | 78.4M +117.96% | 36.0M -48.23% | |
Total Shares Outstanding | 28.0M +86.37% | 15.0M +34.56% | 11.2M -70.66% | 38.0M +0.50% | |
Cash Flow | |||||
Cash from Operating Activities | -77.2M +23.26% | -62.6M +20.23% | -52.1M +13.54% | -45.9M +36.17% | |
Capital Expenditures | 7,000 -98.73% | 552,000 +106.74% | 267,000 -53.65% | 576,000 -76.28% | |
Cash from Investing Activities | 5,000 +100.94% | -532,000 +99.25% | -267,000 -53.65% | -576,000 -76.28% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 34.2M -28.55% | 47.9M -52.58% | 101.0M +183,483.64% | 55,000 -99.95% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | 27,992.28% N/A | N/A N/A | |
Return on Assets | -131.06% +60.71% | -81.55% -9.39% | -90.00% +69.58% | -53.07% +68.82% | |
Return on Equity | -230.31% +126.39% | -101.73% -9.71% | -112.67% +57.73% | -71.44% -13.12% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 2.62 -47.25% | 4.98 -30.78% | 7.19 +21.68% | 5.91 -46.06% | |
Cash Ratio | 2.17 -53.77% | 4.70 -33.04% | 7.02 +29.70% | 5.41 -48.74% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow